- Home
- MIRM vs LYFT Comparison
MIRM vs LYFT Comparison
Compare MIRM & LYFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | LYFT |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.2B |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MIRM | LYFT |
|---|---|---|
| Price | $101.26 | $14.13 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 29 |
| Target Price | ★ $119.85 | $20.07 |
| AVG Volume (30 Days) | 1.0M | ★ 14.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 74.59 | ★ 11250.00 |
| EPS | N/A | ★ 0.04 |
| Revenue | $19,138,000.00 | ★ $6,316,261,000.00 |
| Revenue This Year | $26.22 | $17.33 |
| Revenue Next Year | $22.04 | $12.29 |
| P/E Ratio | ★ N/A | $345.88 |
| Revenue Growth | N/A | ★ 9.16 |
| 52 Week Low | $43.50 | $12.46 |
| 52 Week High | $114.99 | $25.54 |
Technical Indicators
Market Signals| Indicator | MIRM | LYFT |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 55.96 |
| Support Level | $95.68 | $12.80 |
| Resistance Level | $107.51 | $14.24 |
| Average True Range (ATR) | 5.22 | 0.59 |
| MACD | -0.65 | 0.05 |
| Stochastic Oscillator | 33.42 | 67.23 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.